All Curated Mutation Sites in HBV 
Back to Mutation Home

 The Virus Mutation(VM) module provides researchers the annotations of reported pathogenic mutations in HBV related to human diseases. The curated VM information includes mutation site, mutation level, virus gene/protein/region, virus-associated disease, genotype/subtype, literature evidence, etc.


Browse Data by Virus Gene/Protein/Region, Disease OR Description
*Please select one option you are interested in, the page will be automatically redirected.
     
     

For highly variable viruses (e.g., HBV, HIV, SARS-CoV-2), ViMIC defaults to displaying mutations in a specific region. Click the green button to search for other regions, or click "Show All" to view all mutations (loading speed may be affected by network conditions).

Show All
  
S
  
BCP
  
X
  
C
  
Core Promoter
  
Core Upstream Regulatory Sequence
  
DR1
  
EnhI
  
EnhII
  
PreC
  
P
  
PreC Promoter
  
PreS
  
PreS1
  
PreS1 Promoter
  
PreS2
  
RT
  
S Promoter
  
S1 Promoter
  
S2 Promoter
  
X Promoter
  

Keyword: S Promoter
ID PMID Mutation Gene/Protein/Region Encoding Gene/Protein Disease Description Detail
1 30669266 A115C
S Promoter
Hepatitis B, Chronic
G
S
C
L
View
2 30669266 C18T
S Promoter
Hepatitis B, Chronic
G
S
C
L
View
3 30669266 G82A
S Promoter
Hepatitis B, Chronic
G
S
C
L
View
4 30669266 G120A
S Promoter
Hepatitis B, Chronic
G
S
C
L
View
5 30669266 A138G
S Promoter
Hepatitis B, Chronic
G
S
C
L
View
6 30669266 A75T
S Promoter
Hepatitis B, Chronic
G
S
C
L
View
7 30669266 C189A
S Promoter
Hepatitis B, Chronic
G
S
C
L
View
8 30669266 C44T
S Promoter
Hepatitis B, Chronic
G
S
C
L
View
9 30669266 G129A
S Promoter
Hepatitis B, Chronic
G
S
C
L
View
10 30669266 G228A
S Promoter
Hepatitis B, Chronic
G
S
C
L
View
11 30669266 T118C
S Promoter
Hepatitis B, Chronic
G
S
C
L
View
12 30669266 T134C
S Promoter
Hepatitis B, Chronic
G
S
C
L
View
Contents
Description

The table shows all curated mutation sites of HBV in each literature

Table Description Column Note
D
The study mentioned a certain treatment method, such as drug resistance caused by mutations.
G
The study mentioned the virus genotype/subtype information.
R
The study mentioned the reference sequence used for comparison, or the original strain of the virus used for site-directed mutagenesis.
S
The study provided sequence information or accession numbers.
L
The study provided the geographic region/country of data origin.
C
The study provided clinical baseline information.
I
The study involved information related to immune.
T
The study involved host target genes.